Patents by Inventor Michael Xia

Michael Xia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8470827
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: June 25, 2013
    Assignee: Incyte Corporation
    Inventors: Chu-Biao Xue, Changsheng Zheng, Hao Feng, Michael Xia, Joseph Glenn, Ganfeng Cao, Brian W. Metcalf
  • Patent number: 8410265
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: April 2, 2013
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W. Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, James D. Rodgers, Haisheng Wang
  • Publication number: 20120202202
    Abstract: Provided are new and improved methods for detecting circulating tumor cells and tumor cell DNA in patient blood or other biofluid samples. Particular aspects comprise three steps: DNA extraction from patient samples, DNA digestion with multiple selected methylation-sensitive enzymes, and target amplification by a conventional or a real-time PCR with specific probe and/or primers. Also provided are a total of 40 tumor-specific DNA methylation loci as biomarkers having substantial utility and specificity in major types of human malignancies including hematopoietic and solid tumors.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 9, 2012
    Inventors: Michael Xia WANG, Charles W. Caldwell, Kristen H. Taylor, Srilatha Nalluri, Dali Zheng
  • Publication number: 20120077798
    Abstract: The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    Type: Application
    Filed: December 9, 2011
    Publication date: March 29, 2012
    Inventors: James D. RODGERS, Stacey SHEPARD, Yun-Long LI, Jiacheng ZHOU, Pingli LIU, David MELONI, Michael XIA
  • Publication number: 20120035172
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: October 17, 2011
    Publication date: February 9, 2012
    Applicant: INCYTE CORPORATION
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Fen Ye, Brian Metcalf
  • Patent number: 8039478
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: October 18, 2011
    Assignee: Incyte Corporation
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Fen Ye, Brian Metcalf
  • Publication number: 20100248228
    Abstract: The present invention provides a detecting method of detecting malignant cells in a patient's specimen or a biological sample. Specifically, the inventive method includes the steps of extracting a genomic DNA, digesting said genomic DNA with one or multiple methylation sensitive restriction enzymes, and amplifying by PCR with one or multiple selected primers. The PCR can be performed in a conventional or a real-time platform. The inventive method can detect leukemia cells in 90% ALL patients at a sensitivity of up to 10?6. The inventive method also provides broad clinical applications in cancer (including hematopoietic and solid tumors) screening and risk assessment, early detection and diagnosis confirmation, and therapeutic monitoring, minimal residual disease detection and prognostic prediction.
    Type: Application
    Filed: March 27, 2009
    Publication date: September 30, 2010
    Applicant: The Curators of the University of Missouri
    Inventors: Michael Xia Wang, Huidong Shi, Srilatha Nalluri
  • Publication number: 20100190981
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Application
    Filed: January 14, 2010
    Publication date: July 29, 2010
    Inventors: Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W. Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, James D. Rodgers, Haisheng Wang
  • Publication number: 20100119503
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Application
    Filed: September 25, 2008
    Publication date: May 13, 2010
    Applicant: INCYTE CORPORATION
    Inventors: Chu-Biao Xue, Changsheng Zheng, Hao Feng, Michael Xia, Joseph Glenn, Ganfeng Cao, Brian W. Metcalf
  • Publication number: 20090286774
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: November 3, 2008
    Publication date: November 19, 2009
    Applicant: INCYTE CORPORATION
    Inventors: Changsheng ZHENG, Chu-Biao XUE, Ganfeng CAO, Michael XIA, Anlai WANG, Hai Fen YE, Brian METCALF
  • Patent number: 7618970
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: November 17, 2009
    Assignee: Incyte Corporation
    Inventors: Chu-Biao Xue, Changsheng Zheng, Hao Feng, Michael Xia, Joseph Glenn, Ganfeng Cao, Brian W. Metcalf
  • Publication number: 20090233903
    Abstract: The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    Type: Application
    Filed: March 10, 2009
    Publication date: September 17, 2009
    Applicant: INCYTE CORPORATION
    Inventors: James D. Rodgers, Stacey Shepard, Yun-Long Li, Jiacheng Zhou, Pingli Liu, David Meloni, Michael Xia
  • Publication number: 20090208485
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Application
    Filed: April 29, 2009
    Publication date: August 20, 2009
    Inventors: Chu-Biao Xue, Changsheng Zheng, Hao Feng, Michael Xia, Joseph Glenn, Ganfeng Cao, Brian W. Metcalf
  • Patent number: 7511050
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: March 31, 2009
    Assignee: Incyte Corporation
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Fen Ye, Brian Metcalf
  • Patent number: 7449467
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: November 11, 2008
    Assignee: Pfizer Inc.
    Inventors: Chu-Biao Xue, Changsheng Zheng, Hao Feng, Michael Xia, Joseph Glenn, Ganfeng Cao, Brian W. Metcalf
  • Publication number: 20080045554
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: June 22, 2007
    Publication date: February 21, 2008
    Applicant: Incyte Corporation
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Ye, Brian Metcalf
  • Patent number: 7307086
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: December 11, 2007
    Assignee: Incyte Corporation
    Inventors: Chu-Biao Xue, Changsheng Zheng, Ganfeng Cao, Hao Feng, Michael Xia, Rajan Anand, Joseph Glenn, Brian W. Metcalf
  • Publication number: 20060020133
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Application
    Filed: June 27, 2005
    Publication date: January 26, 2006
    Inventors: Chu-Biao Xue, Changsheng Zheng, Hao Feng, Michael Xia, Joseph Glenn, Ganfeng Cao, Brian Metcalf
  • Publication number: 20060004018
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Application
    Filed: June 27, 2005
    Publication date: January 5, 2006
    Inventors: Chu-Biao Xue, Changsheng Zheng, Hao Feng, Michael Xia, Joseph Glenn, Ganfeng. Cao, Brian Metcalf
  • Publication number: 20050267146
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Application
    Filed: May 10, 2005
    Publication date: December 1, 2005
    Inventors: Chu-Biao Xue, Changsheng Zheng, Ganfeng Cao, Hao Feng, Michael Xia, Rajan Anand, Joseph Glenn, Brian Metcalf